UK Preclinical Imaging Market (2024-2029)
The UK Preclinical Imaging Market was valued at $27.6 Million in 2024 and projected to reach to $33.1 Million by 2029, representing a compound annual growth rate of 3.7%. The UK preclinical imaging market is positioned for steady growth through 2029, supported by continued investment in pharmaceutical research and development across both academic and commercial sectors.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Preclinical Imaging Market Trends and Insights
- The UK market benefits from strong pharmaceutical research infrastructure, leading academic institutions, and substantial investment in drug discovery and development.
- The UK's regulatory environment and collaborative research ecosystem continue to drive adoption of advanced preclinical imaging technologies across universities, contract research organizations, and pharmaceutical companies. Growth in the UK preclinical imaging market is supported by increasing demand for non-invasive imaging modalities in early-stage drug development and the UK's commitment to life sciences innovation.
- The UK market reflects steady expansion driven by technological advancements in imaging resolution, software capabilities, and multimodal imaging systems.
- Between 2024 and 2029, the UK is expected to maintain moderate growth as research institutions and biotech firms invest in cutting-edge preclinical imaging platforms to accelerate translational research and reduce time-to-market for new therapeutics..
Key Market Statistics
- CAGR (2024-2029) 3.7% CAGR
- Market Size, 2024 ~USD 27.6 Million
- Forecast, 2029 ~USD 33.1 Million
- Country UK
UK Preclinical Imaging Market Overview
Market Valuation :
The UK preclinical imaging market reached $27.6 million in 2024, with projected growth to $33.1 million by 2029, representing a steady 3.7% CAGR driven by robust pharmaceutical R&D activities.
Research Infrastructure :
The UK benefits from world-class academic institutions and research centers including Oxford, Cambridge, and the Francis Crick Institute, which drive significant demand for advanced preclinical imaging technologies.
Regulatory Environment :
The UK's stringent regulatory framework and post-Brexit independent regulatory pathway create opportunities for innovative imaging solutions that support drug discovery and development compliance requirements.
Investment in Drug Discovery :
Substantial government and private sector investment in life sciences, coupled with the UK's position as a global biotech hub, fuels continuous adoption of preclinical imaging modalities.
UK Preclinical Imaging Market Dynamics
- The UK's strong life sciences ecosystem, combined with collaborative research initiatives and access to cutting-edge facilities, will sustain demand for advanced imaging technologies.
- However, growth remains moderate compared to global markets, reflecting the UK's mature research infrastructure and selective adoption patterns.
- Emerging applications in personalized medicine and increased focus on reducing animal testing through advanced imaging will provide incremental growth opportunities throughout the forecast period..
Market Ecosystem
Related Ecosystem
Diagnostic Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- CT Scanners
- Nuclear Imaging
- Positron Emission Tomography
- Siemens healthineers
- PHILIPS HEALTHCARE
- CANON INC.
- FUJIFILM Holdings Corporation
- UNITED IMAGING HEALTHCARE CO., LTD.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- The UK preclinical imaging market is valued at $27.6 million in 2024 and will reach $33.1 million by 2029 at a 3.7% CAGR.
- The UK's strong academic research base and pharmaceutical sector drive steady demand for advanced preclinical imaging technologies.
- Non-invasive imaging modalities and multimodal systems are key growth drivers in the UK market between 2024 and 2029.
- The UK's life sciences innovation strategy and regulatory framework support continued investment in preclinical imaging infrastructure.
Preclinical Imaging Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | NUCLEAR IMAGING SYSTEMS (Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 5% from 2024 to 2029 |
| Largest Segment | PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 4 (2024) |
| Revenue Forecast (Billions) | ~USD 5.1 (2029) |
| Segments Covered | Product, Type, Application, End User |
UK Preclinical Imaging Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product
- Imaging Systems
- Reagents
- Software
By Type
- Barium-Based Contrast Agents
- Bioluminescence Imaging Systems
- Fluorescence Imaging Systems
- Gadolinium-Based Contrast Agents
- Gallium-67-Based Spect Probes
- Gastrografin-Based Contrast Agents
- Gold Nanoparticles
- Iodine-131-Based Spect Probes
- Iodine-Based Contrast Agents
- Iron-Based Contrast Agents
- Magnetic Particle Imaging Systems
- Manganese-Based Contrast Agents
- Micro-Ct Systems
- Micro-Mri Systems
- Micro-Ultrasound Systems
- Nuclear Imaging Systems
- Optical Imaging Systems
- Other Optical Imaging Systems
- Other Spect Probes
- Photoacoustic Imaging Systems
- Technetium-99M-Based Spect Probes
- Thallium-201-Based Spect Probes
By Application
- Cardiology
- Immunology & Inflammation
- Infectious Diseases
- Neurology
- Oncology
- Other Applications
By End User
- Academic & Research Centers
- Imaging Centers
- Other End Users
- Pharmaceutical & Biotechnology Companies
UK: PRECLINICAL IMAGING MARKET, BY END USER, 2023–2029
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH CENTERS | 43.4 | 45.5 | 47.6 | 49.8 | 52.2 | 54.6 | 57.2 | 4.7 |
| IMAGING CENTERS | 24.4 | 25.7 | 27 | 28.4 | 29.8 | 31.3 | 32.9 | 5.1 |
| OTHER END USERS | 10.9 | 11.2 | 11.6 | 12 | 12.4 | 12.8 | 13.2 | 3.3 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 192.7 | 201.2 | 210 | 219.3 | 228.9 | 238.9 | 249.3 | 4.4 |
| TOTAL | 271.5 | 283.6 | 296.2 | 309.4 | 323.2 | 337.6 | 352.6 | 4.5 |
Target Audience
- Pharmaceutical Companies : UK-based and international pharma firms need market intelligence to optimize R&D investments, identify partnership opportunities with UK research institutions, and plan product launches tailored to UK regulatory requirements.
- Medical Device Manufacturers : Imaging technology providers require UK market data to assess market penetration opportunities, benchmark against competitors, and develop go-to-market strategies for the UK's sophisticated research community.
- Academic & Research Institutions : UK universities and research centers need market insights to justify equipment investments, identify funding opportunities, and understand technology trends shaping preclinical research capabilities.
- Investment & Venture Capital Firms : Investors targeting the UK life sciences sector require detailed market analysis to evaluate portfolio companies, identify acquisition targets, and assess growth potential in preclinical imaging technologies.
- Healthcare Consultants & Analysts : Consulting firms and market analysts need UK-specific data to support client advisory services, competitive benchmarking, and strategic planning for healthcare and pharmaceutical sector clients.
Key Companies in the UK Preclinical Imaging Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| ANALOGIC CORPORATION | United States | Private Company | MRI,PET,SPECT, |
| XILINX, INC. | United States | Private Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| GUERBET GROUP | France | InvalidIdentifier | PET,SPECT,MRI, |
| BRUKER CORPORATION | United States | Public Company | MRI,PET,SPECT, |
| REVVITY, INC. | United States | Public Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| OPTISCAN IMAGING LTD. | Australia | Public Company | Optical Imaging (Bioluminescance),PET,SPECT, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and life sciences sector.
ANALOGIC CORPORATION
Analogic Corporation is a United States-based private company founded in 1967 with 1,510 employees, specializing in medical and aerospace technology solutions.
XILINX, INC.
Xilinx, Inc. is a United States-based private company founded in 1984 with 4,890 employees, operating in the semiconductor and programmable logic industry.
GUERBET GROUP
Guerbet Group is a France-based company in the medical imaging and pharmaceutical sector.
BRUKER CORPORATION
Bruker Corporation is a United States-based public company founded in 1960 with 11,085 employees, providing scientific instruments and analytical solutions.
REVVITY, INC.
Revvity, Inc. is a United States-based public company founded in 1937 with 11,000 employees, operating in the life sciences and diagnostics industry.
OPTISCAN IMAGING LTD.
Optiscan Imaging Ltd. is an Australia-based public company founded in 1994 with 9 employees, specializing in optical imaging technology.
Reasons to Buy this Report
- UK-Specific Market Sizing : Obtain precise valuation data for the UK market ($27.6M in 2024) with detailed forecasts through 2029, enabling accurate budget allocation and investment decisions for UK-focused operations.
- Competitive Landscape Intelligence : Understand the competitive dynamics specific to the UK market, including key players, market share distribution, and strategic positioning within the UK's pharmaceutical and academic research sectors.
- Regulatory & Policy Insights : Gain insights into UK-specific regulatory requirements, post-Brexit implications, and government initiatives supporting preclinical research that directly impact market opportunities and growth trajectories.
- Academic & Institutional Opportunities : Identify collaboration and partnership opportunities with leading UK research institutions, universities, and NHS trusts that represent significant end-users of preclinical imaging technologies.
- Growth Driver Analysis : Access detailed analysis of UK-specific growth drivers including investment trends, research funding patterns, and emerging applications in personalized medicine and alternative testing methodologies.
Frequently asked questions
What is the current size of the UK preclinical imaging market?
The UK preclinical imaging market was valued at $27.6 million in 2024.
What is the projected size of the UK preclinical imaging market by 2029?
The UK preclinical imaging market is forecast to reach $33.1 million by 2029.
What is the growth rate of the UK preclinical imaging market?
The UK preclinical imaging market is expected to grow at a compound annual growth rate of 3.7% from 2024 to 2029.
Which sectors drive demand for preclinical imaging in the UK?
The UK pharmaceutical industry, academic research institutions, and contract research organizations are primary drivers of preclinical imaging demand.
What technologies are growing in the UK preclinical imaging market?
Non-invasive imaging modalities, multimodal imaging systems, and advanced software solutions are experiencing growth in the UK market.
RESEARCH METHODOLOGY
This market research study utilized extensive secondary sources, directories, and databases to identify and collect information relevant to this technical, market-oriented, and financial analysis of the preclinical imaging market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to gather and verify critical qualitative and quantitative information, as well as to assess market prospects. The size of the preclinical imaging market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was employed to identify and collect information relevant to the comprehensive, technical, market-oriented, and commercial study of the preclinical imaging market. It was also used to obtain important information about key players, market classification, and segmentation according to industry trends, as well as key developments related to market and technology perspectives, down to the most detailed level. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after acquiring a basic understanding of the global preclinical imaging market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital personnel, department heads, hospital directors, corporate personnel) and supply side (such as C-level and D-level executives, technology experts, software developers, marketing and sales managers, among others) across five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Breakdown of Primary Interviews
Note: Tiers are defined based on the total revenues of companies. As of 2024, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the global preclinical imaging market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- Key players in the global preclinical imaging market were identified through secondary research, and their global market shares were determined through primary and secondary research.
- The research methodology included the study of the annual and quarterly financial reports and regulatory filings, data books of major market players, and interviews with industry experts for detailed market insights.
- All percentage shares, splits, and breakdowns for the global preclinical imaging market were determined by using secondary sources and verified through primary sources.
- All key macroindicators affecting the revenue growth of market segments and subsegments have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get validated and verified quantitative and qualitative data.
- The gathered market data was consolidated and added with detailed inputs and analysis and presented in this report.
Global Preclinical Imaging Market: Bottom-up and Top-down Approach
Data Triangulation
After arriving at the overall market size, from the market size estimation process explained above, the preclinical imaging market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the preclinical imaging market.
Market Definition
Preclinical imaging involves the application of molecular imaging for the assessment of anatomical, physiological, and functional parameters in live animal models during preclinical studies. Preclinical imaging systems and reagents are utilized to visualize living animals in order to assess the safety and efficacy of novel drug procedures or other medical treatments for human applications. During preclinical studies, a variety of different imaging modalities are utilized, such as optical imaging systems, nuclear imaging systems (micro-PET and micro-SPECT), micro-MRI, micro-ultrasound systems, and micro-CT imaging systems.
Stakeholders
- Preclinical Imaging Instrument Manufacturers, Suppliers, and Imaging Software Providers
- Pharmaceutical and Biotechnology Companies
- Preclinical Imaging Reagent Manufacturers and Suppliers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Market Research and Consulting Service Providers
Report Objectives
- To define, describe, and forecast the preclinical imaging market by product type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
-
To analyze the opportunities in the market for stakeholders and provide details of
the competitive landscape for preclinical imaging market leaders - To profile the key players in the market and comprehensively analyze their market shares and core competencies
-
To forecast the size of the market segments with respect to five main regions:
North America, the Asia Pacific, Europe, Latin America, and the Middle East & Africa - To track and analyze competitive developments, such as partnerships, acquisitions, product launches & approvals, and expansions
- To benchmark players within the preclinical imaging market using the Competitive Evaluation Matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering
Get the Full Preclinical Imaging Market Report
Full forecast, segment splits, and company analysis for all Preclinical Imaging Market.
- US Preclinical Imaging Market
- Canada Preclinical Imaging Market
- Germany Preclinical Imaging Market
- France Preclinical Imaging Market
- Italy Preclinical Imaging Market
- Spain Preclinical Imaging Market
- Japan Preclinical Imaging Market
- China Preclinical Imaging Market
- India Preclinical Imaging Market
- Brazil Preclinical Imaging Market
- Mexico Preclinical Imaging Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
